Homepage Top Section2

The status was based on efficacy and safety results from HPTN 083 phase IIb/III randomised, multicentre, double-blind and clinical trial. The study compared long-acting and injectable cabotegravir to

The independent and NIH-appointed Data Safety Monitoring Board (DSMB) revealed that the mRNA-1273 candidate has demonstrated an efficacy rate of 94.5% in the first interim analysis of the

Keytruda (pembrolizumab), an anti-PD-1 therapy, works by enhancing the ability of the body’s immune system to identify and fight tumour cells. It is a humanised monoclonal antibody that

The addition of Calquence to best supportive care (BSC) has failed to increase the proportion of patients who remained alive and free of respiratory failure. Calquence, the next-generation

SCD, which is a common single-gene disorder, is estimated to affect over 70,000 in the EU-27 and up to 100,000 people in the US. The status was provided

According to BlueWillow Biologics, the preclinical research shown that the company’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein enabled to significantly neutralise antibody response. The research

The interim analysis showed that BNT162b2 vaccine candidate is over 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. BioNTech co-founder and CEO Ugur

CAN-COVID is a randomised, double-blind and placebo-controlled study designed to evaluate the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalised patients with Covid-19 pneumonia

The EU approval of Forxiga was based on data from the international, multi-centre, parallel-group, randomised and double-blinded DAPA-HF phase III trial. AstraZeneca claims that Forxiga is the first